{
  "extraction_metadata": {
    "timestamp": "2025-10-01T11:46:05.991437",
    "source_type": "hta_submission",
    "indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
    "total_countries": 11,
    "temperature": 0.3
  },
  "outcomes_by_country": {
    "AT": {
      "Indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
      "Country": "AT",
      "Outcomes": "all-cause mortality, overall survival (OS), time to progression (TTP), time to symptomatic progression (TTSP), disease control rate (DCR), tumor response rate, overall response rate (ORR), recurrence-free survival, tumor reduction, adverse events, hand-foot syndrome, diarrhoea, diarrhea, fatigue, rash, skin rash or desquamation, hypertension, pain, jaundice, fever, abdominal swelling, liver failure, post-treatment complications, major complications, complication incidence, toxicity, liver function, quality of life, health-related quality of life, health status, days of missed work, length of hospital stay, EORTC QLQ-C30, EORTC QLQ-HCC18, European Quality of Life – 5 Dimensions Visual Analogue Scale (EQ-5D VAS), cognitive functioning (EORTC QLQ-C30), symptom scales (EORTC QLQ-C30), symptom scales (EORTC QLQ-HCC18), time to deterioration (score increase by at least 10 points over baseline; EORTC QLQ-C30 and EORTC QLQ-HCC18)",
      "ChunksUsed": 35,
      "ContextTokens": 7525
    },
    "CZ": {
      "Indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
      "Country": "CZ",
      "Outcomes": "",
      "ChunksUsed": 1,
      "ContextTokens": 202
    },
    "DE": {
      "Indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
      "Country": "DE",
      "Outcomes": "all-cause mortality, overall survival (OS), time to progression (TTP), time to symptomatic progression (TTSP), disease control rate (DCR), tumor response rate, overall response rate (ORR), tumor reduction, recurrence-free survival, disease progression, local control, length of hospital stay, days of missed work, adverse events, hand-foot syndrome, diarrhoea, diarrhea, fatigue, rash, skin rash or desquamation, hypertension, pain (EORTC QLQ-HCC18), jaundice (EORTC QLQ-HCC18), fever (EORTC QLQ-HCC18), abdominal swelling (EORTC QLQ-HCC18), liver failure, post-treatment complications, major complications, toxicity, health status (EQ-5D visual analogue scale), global health status (EORTC QLQ-C30), cognitive functioning (EORTC QLQ-C30), function scales (EORTC QLQ-C30), function scales (EORTC QLQ-HCC18), symptoms (EORTC QLQ-C30), symptoms (EORTC QLQ-HCC18), time to deterioration (EORTC QLQ-C30, defined as score increase by at least 10 points over baseline), time to deterioration (EORTC QLQ-HCC18, defined as score increase by at least 10 points over baseline), EORTC QLQ-C30, EORTC QLQ-HCC18, EQ-5D visual analogue scale (EQ-5D VAS), quality of life, health-related quality of life",
      "ChunksUsed": 35,
      "ContextTokens": 7591
    },
    "DK": {
      "Indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
      "Country": "DK",
      "Outcomes": "overall survival (OS), progression-free survival (PFS), progression-free survival (PFS; RECIST 1.1), time to progression (TTP), objective response rate (ORR), complete response (CR), partial response (PR), tumour response rate, time to response, duration of response (DoR), disease control rate (DCR; mRECIST), clinical benefit rate (CBR), adverse events (general), serious adverse events, adverse events leading to discontinuation, diarrhoea, nutrition disorder, pain, body image disorder, role functioning deterioration, health-related quality of life (HRQoL), EORTC QLQ-C30, EORTC QLQ-HCC18, EQ-5D, EQ-5D visual analogue scale (VAS), EQ-5D health utility index (HUI), plasma pharmacokinetics parameters, blood and tumour biomarker analysis, cost-effectiveness, quality-adjusted life years (QALYs)",
      "ChunksUsed": 35,
      "ContextTokens": 7261
    },
    "EN": {
      "Indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
      "Country": "EN",
      "Outcomes": "overall survival (OS), progression-free survival (PFS), time to radiological disease progression, time to symptomatic disease progression (FHSI-8 questionnaire), treatment duration, treatment discontinuation, dermatological toxicities, hypertension, haemorrhage, cardiac ischaemia, cardiac infarction, gastrointestinal perforation, hepatic impairment, wound healing complications, hand-foot skin reaction, diarrhoea, adverse events (general), health-related quality of life, quality-adjusted life years (QALYs), cost-effectiveness (incremental cost-effectiveness ratio, ICER), resource use estimates",
      "ChunksUsed": 35,
      "ContextTokens": 6598
    },
    "ES": {
      "Indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
      "Country": "ES",
      "Outcomes": "overall survival (OS; time from randomisation to death from any cause), progression-free survival (PFS; time from randomisation to tumour progression defined by RECIST 1.1 or death from any cause), objective response rate (ORR; percentage of patients with partial or complete response; RECIST 1.1), objective response rate (mRECIST; modified RECIST criteria for liver disease), duration of response (time from partial or complete response to disease progression or exit), deterioration in patient quality of life (EORTC QLQ-C30), deterioration in patient quality of life (EORTC QLQ-HCC18), quality of life (EORTC QLQ-C30), quality of life (EORTC QLQ-HCC18), hypertension, fatigue, proteinuria, increased aspartate aminotransferase (AST), pruritus, diarrhoea, fever, loss of appetite, increased alanine aminotransferase (ALT), constipation, increased serum bilirubin, abdominal pain, nausea, cough, thrombocytopenia, weight loss, epilepsy, palmar rash, asthenia, infusion reaction, gastrointestinal disorders, bleeding, infections, liver disorders, hypothyroidism, hyperthyroidism, diabetes mellitus, hand-foot syndrome, hyporexia, neutropenia, arterial hypertension, adverse events (general), serious adverse events, grade 3-4 adverse events, grade 5 adverse events, need for use of medical resources (hospital medical day), intrahospital administration, outpatient regimen, ambulatory regimen",
      "ChunksUsed": 29,
      "ContextTokens": 7389
    },
    "FR": {
      "Indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
      "Country": "FR",
      "Outcomes": "overall survival (OS), progression-free survival (PFS), progression-free survival (RECIST 1.1), time to progression, objective response rate (ORR), disease control rate, clinical benefit rate, EORTC QLQ-C30, EORTC QLQ-HCC18, EQ-5D-3L, hypertension, diarrhoea, decreased appetite, weight loss, fatigue, hand-foot syndrome, proteinuria, dysphonia, alopecia, hepatic encephalopathy, hepatic insufficiency, ascites, tumour progression, abdominal pain, brain haemorrhage, sepsis, brain/gastrointestinal bleeding, intestinal failure, respiratory failure, cerebral vascular accident, cardiovascular arrest, myocardial infarction, haemorrhage, sudden death, hepatotoxicity, haemorrhagic events, hypothyroidism, arterial thromboembolic events, renal impairment, increased bilirubin, hepatic failure, reversible posterior encephalopathy syndrome, hypokalemia, heart failure, QTc prolongation, hypocalcaemia, hyperthyroidism, gastrointestinal perforations, gastrointestinal fistulas, non-gastrointestinal fistulas, venous thromboembolic events, renal failure, proteinuria toxicity, haematological toxicity, adverse events (general), treatment-related deaths, treatment discontinuation due to adverse events, quality-adjusted life years (QALYs), cost-effectiveness (incremental cost-effectiveness ratio, ICER)",
      "ChunksUsed": 35,
      "ContextTokens": 8433
    },
    "NL": {
      "Indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
      "Country": "NL",
      "Outcomes": "overall survival, time to symptom progression, time to progression, disease control, partial response, minor response (reduction of tumour size by 25 to 50%), stable disease (for at least 16 weeks), fatigue, bleeding, abdominal pain, hypertension (grade 3/4), diarrhoea (grade 3/4), lymphoedema (grade 3/4), hand feeding reactions (grade 3/4), adverse reactions (general), serious adverse reactions (grade 3/4), cost-effectiveness analysis, costs of treatment",
      "ChunksUsed": 30,
      "ContextTokens": 4583
    },
    "PO": {
      "Indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
      "Country": "PO",
      "Outcomes": "overall survival (OS), progression-free survival (PFS), time to progression (TTP), objective response rate (ORR), complete response (CR), partial response (PR), stable disease (SD), disease control rate (DCR), number needed to treat (NNT), number needed to harm (NNH), hazard ratio (HR), mean difference (MD), relative risk (RR), risk difference (RD), deaths, life years gained (LYG), quality-adjusted life years (QALYs), cost-effectiveness (incremental cost-effectiveness ratio, ICER), FACT-G (Functional Assessment of Cancer Therapy – General), EQ-5D (Euro QoL – 5 dimensions), EQ VAS (Euro QoL visual analogue scale), infections, lymphopenia, anorexia, hypophosphataemia, haemorrhage, hypertension, diarrhoea, nausea, vomiting, constipation, dry skin, rash, alopecia, hand-foot skin reaction, erythema, pruritus, arthralgia, fatigue, pain, fever, decreased weight, increased amylase, increased lipase, folliculitis, leukopenia, neutropenia, anaemia, thrombocytopenia, hypothyroidism, hypocalcaemia, hypokalaemia, hyponatraemia, hypoglycaemia, depression, peripheral sensory neuropathy, dysgeusia, tinnitus, congestive heart failure, myocardial ischaemia, myocardial infarction, flushing, rhinorrhoea, dysphonia, stomatitis, dyspepsia, dysphagia, gastro oesophageal reflux disease, keratoacanthoma, squamous cell cancer of the skin, dermatitis exfoliative, acne, skin desquamation, hyperkeratosis, myalgia, muscle spasms, renal failure, proteinuria, erectile dysfunction, asthenia, influenza like illness, mucosal inflammation, transient increase in transaminases, secondary cancer, dyspnoea, pleural effusion, cough, back pain, limb pain, acute generalised exanthematous pustulosis, aneurysm, artery dissection, adverse events (general), adverse events (grade 3 or 4), adverse events (treatment-emergent), adverse events (serious)",
      "ChunksUsed": 35,
      "ContextTokens": 8051
    },
    "PT": {
      "Indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
      "Country": "PT",
      "Outcomes": "overall survival (OS), progression-free survival (PFS), progression-free survival (modified RECIST criteria), time to progression (TTP), objective response rate (ORR), quality of life, EORTC QLQ-C30, EORTC QLQ-HCC18, pharmacokinetic parameters, vital signs, laboratory haematological testing, laboratory biochemical testing, urinalysis, electrocardiography, adverse events, adverse events (graded according to the National Cancer Institute), grade 3 adverse reactions, grade 4 adverse reactions, treatment-related mortality, dropout rate for toxicity",
      "ChunksUsed": 22,
      "ContextTokens": 3419
    },
    "SE": {
      "Indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
      "Country": "SE",
      "Outcomes": "overall survival (OS, defined as time from randomization to death from any cause), progression-free survival (PFS), objective tumour response, time to tumour progression, adverse reactions leading to discontinuation of treatment, quality of life (EQ-5D-5L), quality of life (EQ-5D-3L, converted weights with Dolan tariff), quality-adjusted life years (QALYs), cost-effectiveness (cost per QALY), Eastern Cooperative Oncology Group Performance Status (ECOG PS), Child-Pugh scale, adverse events (general), adverse reactions of grade 3 or higher",
      "ChunksUsed": 35,
      "ContextTokens": 6333
    }
  }
}